gip glp 1 agonists The activity of GLP-1 and for Type 2 Diabetes and Obesity Upcoming wave of hormone-based therapies

Outeirino-Iglesias, V., Romani-Perez, M., Gonzalez-Matias, L

In a recent phase II trial with subcutaneous semaglutide, when doses were escalated relatively rapidly to 16 mg weekly, participants experienced additional weight loss, but at the expense of more adverse effects (21)

Most autoimmune patients have subclinical metabolic inflammation that exists independently of their autoimmune condition but amplifies it

Glucagon-like Peptide-1 Attenuates Endothelial Barrier Injury in Diabetes via cAMP/PKA Mediated Down-Regulation of MLC Phosphorylation

Most commercial insurance plans require prior authorization for GLP-1s used for weight loss, and most demand documentation of BMI plus a prior attempt at structured weight management